Restructuring and Impairment (Tables)

9 Months Ended

Sep. 30, 2025

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Impairment

In connection with our 2022 and 2023 Restructuring Plans, restructuring and impairment includes the following (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Impairment of right-of-use assets and property, plant and equipment	$	—	$	—	$	—	$	8,329
Contract termination and other restructuring costs		140		46		756		5,981
Restructuring and impairment	$	140	$	46	$	756	$	14,310

The following is a reconciliation of the impairment charges we recorded for the three and nine months ended September 30, 2024, including the net book values of the sublease assets before the impairment and the fair values of the sublease assets (in thousands):


	Nine Months Ended September 30, 2024
	Property, Plant and Equipment			Operating Lease Right-of-Use Assets			Total
Net book value of impaired facilities before write-off	$	1,897		$	12,506		$	14,403
Less: Fair value of impaired facilities — Level 3 of Fair Value Hierarchy		(855	)		(5,219	)		(6,074	)
Total impairment of right-of-use assets and property, plant and equipment	$	1,042		$	7,287		$	8,329

The following are reconciliations of the contract termination and other costs for three and nine months ended September 30, 2025 and 2024 (in thousands):


	For the Nine Months Ended September 30,
	2025			2024
Liability balances as of December 31, 2024 and 2023, respectively	$	9,078		$	5,542
Expense recognized during the period		169			975
Payments during the period		(554	)		(928	)
Liability balances as of March 31, 2025 and 2024, respectively	$	8,693		$	5,589
Expense recognized during the period		447			4,960
Payments during the period		(836	)		(887	)
Liability balances as of June 30, 2025 and 2024, respectively	$	8,304		$	9,662
Expense recognized during the period		140			46
Payments during the period		(836	)		(886	)
Liability balances as of September 30, 2025 and 2024, respectively	$	7,608		$	8,822

NEKTAR THERAPEUTICS 10-Q